These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 30390575

  • 1. Tumor uptake and tumor/blood ratios for [89Zr]Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1.
    Al-Saden N, Cai Z, Reilly RM.
    Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET.
    Raavé R, Sandker G, Adumeau P, Jacobsen CB, Mangin F, Meyer M, Moreau M, Bernhard C, Da Costa L, Dubois A, Goncalves V, Gustafsson M, Rijpkema M, Boerman O, Chambron JC, Heskamp S, Denat F.
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
    [Abstract] [Full Text] [Related]

  • 7. Site-specifically labeled 89Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model.
    Kristensen LK, Christensen C, Jensen MM, Agnew BJ, Schjöth-Frydendahl C, Kjaer A, Nielsen CH.
    Theranostics; 2019 Aug; 9(15):4409-4420. PubMed ID: 31285769
    [Abstract] [Full Text] [Related]

  • 8. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, Hill GC, Jacobs PM, Tatum JL, Doroshow JH, Kalen JD.
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [Abstract] [Full Text] [Related]

  • 9. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
    Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS.
    PLoS One; 2010 Jan 25; 5(1):e8859. PubMed ID: 20111600
    [Abstract] [Full Text] [Related]

  • 10. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM.
    J Nucl Med; 2009 Aug 25; 50(8):1340-8. PubMed ID: 19617342
    [Abstract] [Full Text] [Related]

  • 11. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
    McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM.
    J Nucl Med; 2009 Nov 25; 50(11):1848-56. PubMed ID: 19837760
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR.
    Chan C, Fonge H, Lam K, Reilly RM.
    Nucl Med Biol; 2020 Nov 25; 80-81():37-44. PubMed ID: 31706737
    [Abstract] [Full Text] [Related]

  • 13. 111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection.
    Cai Z, Chattopadhyay N, Yang K, Kwon YL, Yook S, Pignol JP, Reilly RM.
    Nucl Med Biol; 2016 Dec 25; 43(12):818-826. PubMed ID: 27788375
    [Abstract] [Full Text] [Related]

  • 14. Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
    Lam K, Chan C, Reilly RM.
    MAbs; 2017 Jan 25; 9(1):154-164. PubMed ID: 27813707
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
    Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, Lapi SE.
    Mol Pharm; 2014 Nov 03; 11(11):3988-95. PubMed ID: 25058168
    [Abstract] [Full Text] [Related]

  • 16. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
    Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P.
    Ann Oncol; 2016 Apr 03; 27(4):619-24. PubMed ID: 26598545
    [Abstract] [Full Text] [Related]

  • 17. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging.
    McKnight BN, Viola-Villegas NT.
    Breast Cancer Res; 2018 Oct 25; 20(1):130. PubMed ID: 30359299
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET.
    Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, Mari C, Visser GWM, Valverde IE, Gasser G, Mindt TL, van Dongen GAMS.
    Eur J Nucl Med Mol Imaging; 2017 Feb 25; 44(2):286-295. PubMed ID: 27573793
    [Abstract] [Full Text] [Related]

  • 19. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu.
    Cai Z, Yook S, Lu Y, Bergstrom D, Winnik MA, Pignol JP, Reilly RM.
    Pharm Res; 2017 Mar 25; 34(3):579-590. PubMed ID: 27987070
    [Abstract] [Full Text] [Related]

  • 20. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.
    Chan C, Scollard DA, McLarty K, Smith S, Reilly RM.
    EJNMMI Res; 2011 Aug 17; 1(1):15. PubMed ID: 22214307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.